A General Hypoxia‐Responsive Molecular Container for Tumor‐Targeted Therapy

Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC...

Full description

Saved in:
Bibliographic Details
Published inAdvanced materials (Weinheim) Vol. 32; no. 28; pp. e1908435 - n/a
Main Authors Zhang, Tian‐Xing, Zhang, Zhan‐Zhan, Yue, Yu‐Xin, Hu, Xin‐Yue, Huang, Fan, Shi, Linqi, Liu, Yang, Guo, Dong‐Sheng
Format Journal Article
LanguageEnglish
Published Germany Wiley Subscription Services, Inc 01.07.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia‐targeted drug‐delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor‐targeted drug‐release with reduced side effects. CAC4A fulfils all essential requirements for a drug‐delivery system in addition to multiple advantages, including facile preparation, well‐defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench‐to‐bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug‐delivery systems. Carboxylated azocalix[4]arene is designed as a hypoxia‐responsive molecular container, which affords strong binding toward a series of chemotherapeutic drugs, and improves the drugs’ solubility and stability, demonstrating its universality as a supramolecular drug carrier. Taking one supramolecular prodrug as an example, the efficacy of this hypoxia‐targeted therapy is validated in vitro and in vivo.
AbstractList Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia‐targeted drug‐delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor‐targeted drug‐release with reduced side effects. CAC4A fulfils all essential requirements for a drug‐delivery system in addition to multiple advantages, including facile preparation, well‐defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench‐to‐bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug‐delivery systems.
Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug-delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia-responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia-targeted drug-delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor-targeted drug-release with reduced side effects. CAC4A fulfils all essential requirements for a drug-delivery system in addition to multiple advantages, including facile preparation, well-defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench-to-bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug-delivery systems.Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug-delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia-responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia-targeted drug-delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor-targeted drug-release with reduced side effects. CAC4A fulfils all essential requirements for a drug-delivery system in addition to multiple advantages, including facile preparation, well-defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench-to-bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug-delivery systems.
Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too complex and irreproducible for practical use. In this work, the design of a hypoxia‐responsive molecular container based on calixarene, called CAC4A, which presents a significant advance in practical, hypoxia‐targeted drug‐delivery, is reported. CAC4A enables a wide variety of clinical drugs to be quantitatively loaded to improve their solubility and stability, as well as enable the administration of reduced doses. Furthermore, as a result of its azo functional groups, which are sensitive to reduction within a hypoxic environment, it is possible to achieve tumor‐targeted drug‐release with reduced side effects. CAC4A fulfils all essential requirements for a drug‐delivery system in addition to multiple advantages, including facile preparation, well‐defined molecular weight, and structure, and universal applicability. Such features collectively enable supramolecular prodrugs to be formulated simply and reproducibly, with potential for bench‐to‐bedside translation. Moreover, CAC4A is amenable to other therapy modalities and can be facilely decorated with functional groups and hybridized with nanomaterials, providing ample possibilities for its role in future drug‐delivery systems. Carboxylated azocalix[4]arene is designed as a hypoxia‐responsive molecular container, which affords strong binding toward a series of chemotherapeutic drugs, and improves the drugs’ solubility and stability, demonstrating its universality as a supramolecular drug carrier. Taking one supramolecular prodrug as an example, the efficacy of this hypoxia‐targeted therapy is validated in vitro and in vivo.
Author Yue, Yu‐Xin
Shi, Linqi
Guo, Dong‐Sheng
Hu, Xin‐Yue
Liu, Yang
Zhang, Tian‐Xing
Zhang, Zhan‐Zhan
Huang, Fan
Author_xml – sequence: 1
  givenname: Tian‐Xing
  surname: Zhang
  fullname: Zhang, Tian‐Xing
  organization: Nankai University
– sequence: 2
  givenname: Zhan‐Zhan
  surname: Zhang
  fullname: Zhang, Zhan‐Zhan
  organization: Nankai University
– sequence: 3
  givenname: Yu‐Xin
  surname: Yue
  fullname: Yue, Yu‐Xin
  organization: Nankai University
– sequence: 4
  givenname: Xin‐Yue
  surname: Hu
  fullname: Hu, Xin‐Yue
  organization: Nankai University
– sequence: 5
  givenname: Fan
  surname: Huang
  fullname: Huang, Fan
  email: huangfan@irm-cams.ac.cn
  organization: Chinese Academy of Medical Science & Peking Union Medical College
– sequence: 6
  givenname: Linqi
  surname: Shi
  fullname: Shi, Linqi
  email: shilinqi@nankai.edu.cn
  organization: Nankai University
– sequence: 7
  givenname: Yang
  surname: Liu
  fullname: Liu, Yang
  email: yliu@nankai.edu.cn
  organization: Nankai University
– sequence: 8
  givenname: Dong‐Sheng
  orcidid: 0000-0002-0765-5427
  surname: Guo
  fullname: Guo, Dong‐Sheng
  email: dshguo@nankai.edu.cn
  organization: Nankai University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32459030$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1P3DAQhq0KVJaPa48oUi-97DL-iuPjals-JBBStT1HXmdSjJI4tZPC3vgJ_EZ-CV4tpRIS4jCay_PMjObdJzud75CQLxRmFICdmKo1MwZUQyG4_EQmVDI6FaDlDpmA5nKqc1Hskf0YbwFA55B_JnucCamBw4Rcz7Mz7DCYJjtf9_7emaeHx58Ye99F9xezK9-gHRsTsoXvBuMSmtU-ZMux9SGhSxN-44BVtrxJQ_r1IdmtTRPx6KUfkF-nP5aL8-nl9dnFYn45tVxtjmKyyK2orcpXBa-0LpRd1UoqhcAFM8hMbWvOKk1FUdSVVIYzC6JgtBIoDD8g37Zz--D_jBiHsnXRYtOYDv0YSyZAcaqEkgn9-ga99WPo0nWJYlxSSJWo4xdqXLVYlX1wrQnr8t-rEjDbAjb4GAPWrwiFcpNFucmifM0iCeKNYN1gBpf-GIxr3tf0VrtzDa4_WFLOv1_N_7vPXGSeaQ
CitedBy_id crossref_primary_10_1002_advs_202104349
crossref_primary_10_1002_ps_7492
crossref_primary_10_1021_acsnano_4c01939
crossref_primary_10_1021_acs_molpharmaceut_2c01079
crossref_primary_10_1021_acsnano_3c04718
crossref_primary_10_1021_acs_analchem_2c00406
crossref_primary_10_1002_anie_202213578
crossref_primary_10_1016_j_biomaterials_2022_121599
crossref_primary_10_1515_mr_2022_0048
crossref_primary_10_1093_rb_rbad087
crossref_primary_10_3390_s24227181
crossref_primary_10_1002_adhm_202302940
crossref_primary_10_1021_acs_analchem_1c03153
crossref_primary_10_1021_acsanm_4c00826
crossref_primary_10_1039_D3CC04159J
crossref_primary_10_1002_adma_202100114
crossref_primary_10_1039_D3SC00107E
crossref_primary_10_1016_j_nantod_2024_102373
crossref_primary_10_1002_ange_202402139
crossref_primary_10_1002_adtp_202400207
crossref_primary_10_1021_acsmaterialslett_4c02496
crossref_primary_10_1002_adma_202206851
crossref_primary_10_1038_s41467_022_33920_7
crossref_primary_10_1038_s41467_025_55905_y
crossref_primary_10_1038_s41467_025_56308_9
crossref_primary_10_1002_wnan_70001
crossref_primary_10_1021_accountsmr_3c00130
crossref_primary_10_3390_s24123743
crossref_primary_10_1038_s41467_022_30012_4
crossref_primary_10_1021_acsami_3c08703
crossref_primary_10_1002_adfm_202213967
crossref_primary_10_1002_cbic_202400426
crossref_primary_10_1186_s12951_023_02062_3
crossref_primary_10_1002_advs_202309517
crossref_primary_10_1007_s11426_024_1971_4
crossref_primary_10_1039_D3MH00018D
crossref_primary_10_1016_j_arabjc_2023_104974
crossref_primary_10_1039_D1SC01888D
crossref_primary_10_1007_s10847_023_01200_6
crossref_primary_10_1039_D0SC05525E
crossref_primary_10_1039_D0MA00625D
crossref_primary_10_1039_D3TB02432F
crossref_primary_10_1080_10717544_2021_2021324
crossref_primary_10_1016_j_ijbiomac_2024_132579
crossref_primary_10_1021_acsnano_4c05693
crossref_primary_10_1007_s11426_024_2231_1
crossref_primary_10_1002_adhm_202401778
crossref_primary_10_1021_acsami_4c09588
crossref_primary_10_1002_mabi_202400626
crossref_primary_10_3390_nano14100864
crossref_primary_10_1002_anie_202009442
crossref_primary_10_1016_j_nantod_2023_102064
crossref_primary_10_1021_acsnano_3c09140
crossref_primary_10_1002_ange_202213578
crossref_primary_10_1002_anie_202008732
crossref_primary_10_1002_adma_202304246
crossref_primary_10_1021_acsnano_1c09505
crossref_primary_10_1002_adma_202304249
crossref_primary_10_1016_j_colsurfb_2024_114383
crossref_primary_10_1002_bkcs_12655
crossref_primary_10_1021_acs_accounts_3c00585
crossref_primary_10_1002_ange_202315990
crossref_primary_10_1002_smll_202202834
crossref_primary_10_1126_sciadv_adp9071
crossref_primary_10_1002_adhm_202201889
crossref_primary_10_1002_anie_202402139
crossref_primary_10_1126_sciadv_adk0716
crossref_primary_10_3390_ijms232314889
crossref_primary_10_1039_D4TB02400A
crossref_primary_10_1002_ange_202009442
crossref_primary_10_1002_smll_202006223
crossref_primary_10_1039_D2NA00420H
crossref_primary_10_1002_adma_202403296
crossref_primary_10_1002_advs_202404731
crossref_primary_10_1002_adhm_202400747
crossref_primary_10_1002_adtp_202100176
crossref_primary_10_1039_D3CC01405C
crossref_primary_10_3390_molecules26185451
crossref_primary_10_1002_anse_202300082
crossref_primary_10_3390_molecules28031241
crossref_primary_10_3390_molecules26133963
crossref_primary_10_1002_adma_202203765
crossref_primary_10_1002_adma_202007719
crossref_primary_10_3389_fchem_2021_710808
crossref_primary_10_1002_adma_202207733
crossref_primary_10_1038_s41467_023_41388_2
crossref_primary_10_1002_anie_202315990
crossref_primary_10_1039_D3NR02968A
crossref_primary_10_1002_smll_202205440
crossref_primary_10_1002_ange_202008732
crossref_primary_10_1007_s12274_022_4332_4
crossref_primary_10_1007_s11426_023_1857_2
crossref_primary_10_1016_j_actbio_2022_05_050
crossref_primary_10_1002_adma_202105348
crossref_primary_10_1021_jacs_2c08144
crossref_primary_10_1002_smll_202100578
crossref_primary_10_1016_j_jconrel_2024_03_017
crossref_primary_10_1021_acsami_3c11626
crossref_primary_10_1002_agt2_3
crossref_primary_10_1039_D2OB00656A
crossref_primary_10_1021_jacs_4c03238
crossref_primary_10_1007_s11426_024_2301_3
crossref_primary_10_3390_ph16050699
crossref_primary_10_1021_acsami_4c13762
crossref_primary_10_1002_sstr_202200067
crossref_primary_10_1016_j_colsurfb_2023_113395
crossref_primary_10_1021_acs_nanolett_1c00488
crossref_primary_10_1021_acsabm_1c00847
crossref_primary_10_1021_jacs_1c13067
crossref_primary_10_1021_acs_biomac_4c00722
crossref_primary_10_3390_molecules29163828
Cites_doi 10.1002/anie.201709002
10.1016/j.ijpharm.2006.10.044
10.3109/01480545.2011.653490
10.1111/j.1349-7006.2003.tb01395.x
10.1021/cr500392w
10.1002/adma.201203229
10.1039/C7SC04989G
10.1002/anie.199507131
10.1021/acsami.7b19784
10.1002/adma.201703444
10.1021/acs.chemrev.6b00525
10.1021/acs.chemrev.8b00401
10.1039/C5BM00532A
10.1021/j100096a001
10.1021/ja071090b
10.1021/nn201171r
10.1038/nrc3064
10.1016/S1369-7021(11)70161-4
10.7150/thno.31914
10.1039/C7CS00391A
10.1111/j.2042-7158.2012.01567.x
10.1039/b504487a
10.1039/c000605j
10.1039/C8CS00271A
10.1039/c1sc00231g
10.1111/j.1365-2230.2010.03989.x
10.1038/nnano.2011.166
10.1002/anie.201511432
10.1063/1.1677527
10.1039/C7CP02110K
10.1073/pnas.1204600109
10.1021/acsami.7b01157
10.1016/j.addr.2007.05.006
10.1002/chem.200900165
10.1016/j.addr.2012.01.015
10.1021/acs.chemrev.5b00046
10.1021/cr970025p
10.1007/s10847-014-0412-8
10.1039/C2CS35233H
10.1007/BF00533485
10.1038/s41565-018-0146-7
10.1021/cr200213s
10.1039/C8CS00037A
10.1016/j.addr.2007.05.012
10.1021/ar2000259
10.1038/s41557-018-0164-y
10.1111/cbdd.12818
10.7150/thno.31653
10.1039/C3PY01202F
10.1039/C7CS90102J
10.1002/anie.201813397
10.1038/nchem.1326
10.1039/b813759e
10.1038/nnano.2010.231
10.1038/natrevmats.2016.75
10.1038/nmat2992
10.1002/wnan.1527
10.1021/cr2001178
10.1016/j.addr.2008.02.011
10.1039/C8CS00304A
10.1002/wcms.19
10.1063/1.464913
10.1002/anie.201707164
10.1038/s41570-017-0063
10.1002/adma.201805697
10.1016/S1773-2247(04)50001-1
10.1039/c0nj00285b
10.1039/C6CS00898D
10.1021/ac5039779
10.1007/978-0-387-46312-4
10.1039/C7SC01438D
10.1002/ijch.201900032
10.1021/acs.chemrev.5b00341
10.1021/jacs.8b02331
10.1021/jo00039a027
10.1002/ijch.201100033
10.1074/jbc.273.24.14721
10.1038/nmat3430
10.1016/0022-1759(83)90303-4
ContentType Journal Article
Copyright 2020 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Copyright_xml – notice: 2020 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
– notice: 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
DBID AAYXX
CITATION
NPM
7SR
8BQ
8FD
JG9
7X8
DOI 10.1002/adma.201908435
DatabaseName CrossRef
PubMed
Engineered Materials Abstracts
METADEX
Technology Research Database
Materials Research Database
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Materials Research Database
Engineered Materials Abstracts
Technology Research Database
METADEX
MEDLINE - Academic
DatabaseTitleList CrossRef
PubMed
MEDLINE - Academic
Materials Research Database

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1521-4095
EndPage n/a
ExternalDocumentID 32459030
10_1002_adma_201908435
ADMA201908435
Genre article
Journal Article
GrantInformation_xml – fundername: National Key Research and Development Programs of China
  funderid: 2018YFA0209700
– fundername: Fundamental Research Funds for the Central Universities
– fundername: NSFC
  funderid: 51873090; 31961143004; 21620102005
– fundername: NSFC
  grantid: 51873090
– fundername: NSFC
  grantid: 31961143004
– fundername: National Key Research and Development Program of China
  grantid: 2018YFA0209700
– fundername: NSFC
  grantid: 21620102005
GroupedDBID ---
.3N
.GA
05W
0R~
10A
1L6
1OB
1OC
1ZS
23M
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABPVW
ACAHQ
ACCFJ
ACCZN
ACGFS
ACIWK
ACPOU
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRSTM
EBS
F00
F01
F04
F5P
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
Q.N
Q11
QB0
QRW
R.K
RNS
ROL
RWI
RWM
RX1
RYL
SUPJJ
TN5
UB1
UPT
V2E
W8V
W99
WBKPD
WFSAM
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRC
WXSBR
WYISQ
XG1
XPP
XV2
YR2
ZZTAW
~02
~IA
~WT
.Y3
31~
6TJ
8WZ
A6W
AANHP
AAYOK
AAYXX
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADMLS
ADNMO
AETEA
AEYWJ
AFFNX
AGHNM
AGQPQ
AGYGG
ASPBG
AVWKF
AZFZN
CITATION
EJD
FEDTE
FOJGT
HF~
HVGLF
LW6
M6K
NDZJH
PALCI
RIWAO
RJQFR
SAMSI
WTY
ZY4
NPM
7SR
8BQ
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
JG9
7X8
ID FETCH-LOGICAL-c3735-92586c4fc76b83d9987cbf7577e0342ae2afcf32d91488fd57a32c04821d4e4a3
IEDL.DBID DR2
ISSN 0935-9648
1521-4095
IngestDate Fri Jul 11 11:05:11 EDT 2025
Fri Jul 25 04:54:15 EDT 2025
Wed Feb 19 02:29:51 EST 2025
Thu Apr 24 22:53:05 EDT 2025
Tue Jul 01 02:32:48 EDT 2025
Wed Jan 22 16:34:37 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 28
Keywords hypoxia
drug delivery
calixarene
chemotherapy
supramolecular chemistry
Language English
License 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3735-92586c4fc76b83d9987cbf7577e0342ae2afcf32d91488fd57a32c04821d4e4a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0765-5427
PMID 32459030
PQID 2423510351
PQPubID 2045203
PageCount 11
ParticipantIDs proquest_miscellaneous_2407317475
proquest_journals_2423510351
pubmed_primary_32459030
crossref_primary_10_1002_adma_201908435
crossref_citationtrail_10_1002_adma_201908435
wiley_primary_10_1002_adma_201908435_ADMA201908435
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-07-01
PublicationDateYYYYMMDD 2020-07-01
PublicationDate_xml – month: 07
  year: 2020
  text: 2020-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Weinheim
PublicationTitle Advanced materials (Weinheim)
PublicationTitleAlternate Adv Mater
PublicationYear 2020
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2018 2017 2017 2017 2018; 140 56 9 8 10
2019; 9
2007; 129
1994 1993 1973 1972; 98 98 28 56
2011; 1
2017 2004 2011 2008 2017 2017; 46 14 51 60 46 46
2019; 31
2018 2017 2014 2019 2010 2018 2019; 47 89 80 9 34 9 11
2013; 65
2013 2008 2012; 36 6 4
1995; 34
2013; 42
2019; 58
2011; 10
2006
1992; 57
2017 2019; 117 48
2011; 36
2011; 6
2011; 5
2007; 59
2018; 47
2012 2012 2011; 112 11 44
1998; 273
2016; 55
2016; 4
2012 2011 2013; 109 14 25
1998 2007; 98 329
2014; 5
2017 2019 2019 2015 2015 2019 2017; 1 119 11 115 115 59 2
2003 2011 2015; 94 11 87
2011 2011; 2 111
2010; 46
2015; 115
2017; 56
1983; 65
2018; 30
2017; 19
2005; 3
2010; 5
2012; 64
2009; 15
2018; 13
e_1_2_4_40_1
e_1_2_4_21_1
e_1_2_4_44_1
e_1_2_4_23_1
e_1_2_4_42_1
e_1_2_4_21_2
e_1_2_4_25_1
e_1_2_4_27_1
e_1_2_4_27_3
e_1_2_4_29_1
e_1_2_4_27_2
e_1_2_4_27_4
e_1_2_4_1_1
e_1_2_4_1_3
e_1_2_4_3_1
e_1_2_4_1_2
e_1_2_4_1_5
e_1_2_4_5_1
e_1_2_4_1_4
e_1_2_4_1_7
e_1_2_4_7_1
e_1_2_4_1_6
e_1_2_4_9_1
e_1_2_4_31_2
e_1_2_4_10_1
e_1_2_4_31_1
e_1_2_4_12_1
e_1_2_4_31_3
e_1_2_4_33_1
e_1_2_4_14_1
e_1_2_4_35_1
e_1_2_4_16_1
e_1_2_4_37_2
e_1_2_4_37_1
e_1_2_4_18_1
e_1_2_4_39_1
e_1_2_4_18_2
e_1_2_4_41_1
e_1_2_4_20_2
e_1_2_4_20_1
e_1_2_4_45_1
e_1_2_4_20_3
e_1_2_4_22_1
e_1_2_4_43_1
e_1_2_4_24_2
e_1_2_4_24_1
e_1_2_4_24_4
e_1_2_4_24_3
e_1_2_4_26_1
e_1_2_4_24_6
e_1_2_4_24_5
e_1_2_4_28_1
e_1_2_4_24_7
e_1_2_4_2_1
e_1_2_4_4_1
e_1_2_4_6_1
e_1_2_4_8_2
e_1_2_4_8_1
e_1_2_4_8_3
e_1_2_4_30_1
e_1_2_4_32_1
e_1_2_4_11_1
e_1_2_4_34_1
e_1_2_4_11_2
e_1_2_4_11_3
e_1_2_4_13_1
e_1_2_4_36_1
e_1_2_4_13_2
e_1_2_4_13_3
e_1_2_4_15_1
e_1_2_4_38_1
e_1_2_4_13_4
e_1_2_4_13_5
e_1_2_4_13_6
e_1_2_4_17_1
e_1_2_4_19_2
e_1_2_4_19_1
e_1_2_4_19_4
e_1_2_4_19_3
e_1_2_4_19_5
References_xml – volume: 59
  start-page: 645
  year: 2007
  publication-title: Adv. Drug Delivery Rev.
– volume: 2 111
  start-page: 1722 7941
  year: 2011 2011
  publication-title: Chem. Sci. Chem. Rev.
– volume: 47
  start-page: 5491
  year: 2018
  publication-title: Chem. Soc. Rev.
– volume: 58
  start-page: 2377
  year: 2019
  publication-title: Angew. Chem., Int. Ed.
– volume: 46
  start-page: 3188
  year: 2010
  publication-title: Chem. Commun.
– volume: 3
  start-page: 2122
  year: 2005
  publication-title: Org. Biomol. Chem.
– volume: 9
  start-page: 3041
  year: 2019
  publication-title: Theranostics
– volume: 1
  start-page: 153
  year: 2011
  publication-title: Wiley Interdiscip. Rev.: Comput. Mol. Sci.
– volume: 56
  year: 2017
  publication-title: Angew. Chem., Int. Ed.
– volume: 117 48
  start-page: 6160 771
  year: 2017 2019
  publication-title: Chem. Rev. Chem. Soc. Rev.
– volume: 109 14 25
  start-page: 316 168
  year: 2012 2011 2013
  publication-title: Proc. Natl. Acad. Sci. USA Mater. Today Adv. Mater.
– volume: 47 89 80 9 34 9 11
  start-page: 7006 243 189 3094 2715 2087 86
  year: 2018 2017 2014 2019 2010 2018 2019
  publication-title: Chem. Soc. Rev. Chem. Biol. Drug Des. J. Inclusion Phenom. Macrocyclic Chem. Theranostics New J. Chem. Chem. Sci. Nat. Chem.
– volume: 42
  start-page: 366
  year: 2013
  publication-title: Chem. Soc. Rev.
– volume: 64
  start-page: 764
  year: 2012
  publication-title: Adv. Drug Delivery Rev.
– volume: 112 11 44
  start-page: 2739 1038 893
  year: 2012 2012 2011
  publication-title: Chem. Rev. Nat. Mater. Acc. Chem. Res.
– volume: 94 11 87
  start-page: 1021 393 1274
  year: 2003 2011 2015
  publication-title: Cancer Sci.. Nat. Rev. Cancer Anal. Chem.
– volume: 34
  start-page: 713
  year: 1995
  publication-title: Angew. Chem., Int. Ed. Engl.
– volume: 15
  start-page: 5301
  year: 2009
  publication-title: Chem. ‐ Eur. J.
– volume: 13
  start-page: 746
  year: 2018
  publication-title: Nat. Nanotechnol.
– volume: 129
  start-page: 5362
  year: 2007
  publication-title: J. Am. Chem. Soc.
– volume: 1 119 11 115 115 59 2
  start-page: 0063 1666 1527 7794 913
  year: 2017 2019 2019 2015 2015 2019 2017
  publication-title: Nat. Rev. Chem. Chem. Rev. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. Chem. Rev. Chem. Rev. Isr. J. Chem. Nat. Rev. Mater.
– volume: 10
  start-page: 389
  year: 2011
  publication-title: Nat. Mater.
– volume: 31
  year: 2019
  publication-title: Adv. Mater.
– volume: 4
  start-page: 375
  year: 2016
  publication-title: Biomater. Sci.
– volume: 19
  year: 2017
  publication-title: Phys. Chem. Chem. Phys.
– volume: 59
  start-page: 667
  year: 2007
  publication-title: Adv. Drug Delivery Rev.
– volume: 65
  start-page: 157
  year: 2013
  publication-title: J. Pharm. Pharmacol.
– volume: 5
  start-page: 1503
  year: 2014
  publication-title: Polym. Chem.
– volume: 57
  start-page: 3658
  year: 1992
  publication-title: J. Org. Chem.
– volume: 30
  year: 2018
  publication-title: Adv. Mater.
– volume: 5
  start-page: 5094
  year: 2011
  publication-title: ACS Nano
– volume: 115
  year: 2015
  publication-title: Chem. Rev.
– year: 2006
– volume: 36
  start-page: 645
  year: 2011
  publication-title: Clin. Exp. Dermatol.
– volume: 6
  start-page: 815
  year: 2011
  publication-title: Nat. Nanotechnol.
– volume: 5
  start-page: 833
  year: 2010
  publication-title: Nat. Nanotechnol.
– volume: 98 98 28 56
  start-page: 5648 213 2257
  year: 1994 1993 1973 1972
  publication-title: J. Phys. Chem. J. Chem. Phys. Theor. Chim. Acta J. Chem. Phys.
– volume: 65
  start-page: 55
  year: 1983
  publication-title: J. Immunol. Methods
– volume: 273
  year: 1998
  publication-title: J. Biol. Chem.
– volume: 55
  start-page: 2792
  year: 2016
  publication-title: Angew. Chem., Int. Ed.
– volume: 46 14 51 60 46 46
  start-page: 6600 3 616 1000 6430 7021
  year: 2017 2004 2011 2008 2017 2017
  publication-title: Chem. Soc. Rev. J. Drug Delivery Sci. Technol. Isr. J. Chem. Adv. Drug Delivery Rev. Chem. Soc. Rev. Chem. Soc. Rev.
– volume: 36 6 4
  start-page: 119 4509 503
  year: 2013 2008 2012
  publication-title: Drug Chem. Toxicol. Org. Biomol. Chem. Nat. Chem.
– volume: 98 329
  start-page: 2045 1
  year: 1998 2007
  publication-title: Chem. Rev. Int. J. Pharm.
– volume: 140 56 9 8 10
  start-page: 4945 8602 4458 5365
  year: 2018 2017 2017 2017 2018
  publication-title: J. Am. Chem. Soc. Angew. Chem., Int. Ed. ACS Appl. Mater. Interfaces Chem. Sci. ACS Appl. Mater. Interfaces
– ident: e_1_2_4_12_1
  doi: 10.1002/anie.201709002
– ident: e_1_2_4_18_2
  doi: 10.1016/j.ijpharm.2006.10.044
– ident: e_1_2_4_31_1
  doi: 10.3109/01480545.2011.653490
– ident: e_1_2_4_20_1
  doi: 10.1111/j.1349-7006.2003.tb01395.x
– ident: e_1_2_4_1_4
  doi: 10.1021/cr500392w
– ident: e_1_2_4_11_3
  doi: 10.1002/adma.201203229
– ident: e_1_2_4_24_6
  doi: 10.1039/C7SC04989G
– ident: e_1_2_4_23_1
  doi: 10.1002/anie.199507131
– ident: e_1_2_4_19_5
  doi: 10.1021/acsami.7b19784
– ident: e_1_2_4_5_1
  doi: 10.1002/adma.201703444
– ident: e_1_2_4_21_1
  doi: 10.1021/acs.chemrev.6b00525
– ident: e_1_2_4_1_2
  doi: 10.1021/acs.chemrev.8b00401
– ident: e_1_2_4_7_1
  doi: 10.1039/C5BM00532A
– ident: e_1_2_4_27_1
  doi: 10.1021/j100096a001
– ident: e_1_2_4_6_1
  doi: 10.1021/ja071090b
– ident: e_1_2_4_9_1
  doi: 10.1021/nn201171r
– ident: e_1_2_4_20_2
  doi: 10.1038/nrc3064
– ident: e_1_2_4_11_2
  doi: 10.1016/S1369-7021(11)70161-4
– ident: e_1_2_4_24_4
  doi: 10.7150/thno.31914
– ident: e_1_2_4_13_1
  doi: 10.1039/C7CS00391A
– ident: e_1_2_4_43_1
  doi: 10.1111/j.2042-7158.2012.01567.x
– ident: e_1_2_4_34_1
  doi: 10.1039/b504487a
– ident: e_1_2_4_39_1
  doi: 10.1039/c000605j
– ident: e_1_2_4_24_1
  doi: 10.1039/C8CS00271A
– ident: e_1_2_4_37_1
  doi: 10.1039/c1sc00231g
– ident: e_1_2_4_40_1
  doi: 10.1111/j.1365-2230.2010.03989.x
– ident: e_1_2_4_3_1
  doi: 10.1038/nnano.2011.166
– ident: e_1_2_4_35_1
  doi: 10.1002/anie.201511432
– ident: e_1_2_4_27_4
  doi: 10.1063/1.1677527
– ident: e_1_2_4_29_1
  doi: 10.1039/C7CP02110K
– ident: e_1_2_4_11_1
  doi: 10.1073/pnas.1204600109
– ident: e_1_2_4_19_3
  doi: 10.1021/acsami.7b01157
– ident: e_1_2_4_30_1
  doi: 10.1016/j.addr.2007.05.006
– ident: e_1_2_4_41_1
  doi: 10.1002/chem.200900165
– ident: e_1_2_4_32_1
  doi: 10.1016/j.addr.2012.01.015
– ident: e_1_2_4_1_5
  doi: 10.1021/acs.chemrev.5b00046
– ident: e_1_2_4_18_1
  doi: 10.1021/cr970025p
– ident: e_1_2_4_24_3
  doi: 10.1007/s10847-014-0412-8
– ident: e_1_2_4_15_1
  doi: 10.1039/C2CS35233H
– ident: e_1_2_4_27_3
  doi: 10.1007/BF00533485
– ident: e_1_2_4_44_1
  doi: 10.1038/s41565-018-0146-7
– ident: e_1_2_4_37_2
  doi: 10.1021/cr200213s
– ident: e_1_2_4_17_1
  doi: 10.1039/C8CS00037A
– ident: e_1_2_4_14_1
  doi: 10.1016/j.addr.2007.05.012
– ident: e_1_2_4_8_3
  doi: 10.1021/ar2000259
– ident: e_1_2_4_24_7
  doi: 10.1038/s41557-018-0164-y
– ident: e_1_2_4_24_2
  doi: 10.1111/cbdd.12818
– ident: e_1_2_4_26_1
  doi: 10.7150/thno.31653
– ident: e_1_2_4_4_1
  doi: 10.1039/C3PY01202F
– ident: e_1_2_4_13_5
  doi: 10.1039/C7CS90102J
– ident: e_1_2_4_22_1
  doi: 10.1002/anie.201813397
– ident: e_1_2_4_31_3
  doi: 10.1038/nchem.1326
– ident: e_1_2_4_31_2
  doi: 10.1039/b813759e
– ident: e_1_2_4_10_1
  doi: 10.1038/nnano.2010.231
– ident: e_1_2_4_1_7
  doi: 10.1038/natrevmats.2016.75
– ident: e_1_2_4_2_1
  doi: 10.1038/nmat2992
– ident: e_1_2_4_1_3
  doi: 10.1002/wnan.1527
– ident: e_1_2_4_8_1
  doi: 10.1021/cr2001178
– ident: e_1_2_4_13_4
  doi: 10.1016/j.addr.2008.02.011
– ident: e_1_2_4_21_2
  doi: 10.1039/C8CS00304A
– ident: e_1_2_4_28_1
  doi: 10.1002/wcms.19
– ident: e_1_2_4_27_2
  doi: 10.1063/1.464913
– ident: e_1_2_4_19_2
  doi: 10.1002/anie.201707164
– ident: e_1_2_4_1_1
  doi: 10.1038/s41570-017-0063
– ident: e_1_2_4_45_1
  doi: 10.1002/adma.201805697
– ident: e_1_2_4_13_2
  doi: 10.1016/S1773-2247(04)50001-1
– ident: e_1_2_4_24_5
  doi: 10.1039/c0nj00285b
– ident: e_1_2_4_13_6
  doi: 10.1039/C6CS00898D
– ident: e_1_2_4_20_3
  doi: 10.1021/ac5039779
– ident: e_1_2_4_36_1
  doi: 10.1007/978-0-387-46312-4
– ident: e_1_2_4_38_1
– ident: e_1_2_4_19_4
  doi: 10.1039/C7SC01438D
– ident: e_1_2_4_1_6
  doi: 10.1002/ijch.201900032
– ident: e_1_2_4_16_1
  doi: 10.1021/acs.chemrev.5b00341
– ident: e_1_2_4_19_1
  doi: 10.1021/jacs.8b02331
– ident: e_1_2_4_25_1
  doi: 10.1021/jo00039a027
– ident: e_1_2_4_13_3
  doi: 10.1002/ijch.201100033
– ident: e_1_2_4_33_1
  doi: 10.1074/jbc.273.24.14721
– ident: e_1_2_4_8_2
  doi: 10.1038/nmat3430
– ident: e_1_2_4_42_1
  doi: 10.1016/0022-1759(83)90303-4
SSID ssj0009606
Score 2.6261365
Snippet Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug‐delivery systems are too...
Enhanced drug delivery can improve the therapeutic efficacy of drugs and help overcome side effects. However, many reported drug-delivery systems are too...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e1908435
SubjectTerms calixarene
Calixarenes
Chemical compounds
chemotherapy
Containers
drug delivery
Drug delivery systems
Drugs
Functional groups
Hypoxia
Materials science
Molecular structure
Nanomaterials
Side effects
supramolecular chemistry
Tumors
Title A General Hypoxia‐Responsive Molecular Container for Tumor‐Targeted Therapy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fadma.201908435
https://www.ncbi.nlm.nih.gov/pubmed/32459030
https://www.proquest.com/docview/2423510351
https://www.proquest.com/docview/2407317475
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1bS8MwFMeD7EkfvF_mjQiCT90laZr2cXhhCFMYE3wraZKCqNvQTdQnP4Kf0U_iOellmyKCPpamt6TnnP9JT38h5JDzKJG-Ul4irPR8iEFe1Ahc4ZqIjMWwglMDnYugfeWfX4vrqb_4Mz5EOeGGluH8NRq4Sh7rE2ioMo4bBAEthJAPThgLtlAVdSf8KJTnDrbHhRcFflhQGxusPnv4bFT6JjVnlasLPWdLRBU3nVWc3NbGo6SmX7_wHP_zVMtkMdeltJW9SCtkzvZXycIUrXCNXLZoDqmm7Zfh4PlGfby9d_Ma2ydLO8VKuxSRVwr_KqQgiWlvfD94gKY9V3RuDe1lJIN1cnV22jtue_l6DJ7mEnuQiTDQfqplkITcQKImdZJKIaVFkKCyTKU65cxEkGOFqRFScabBRbCm8a2v-Aap9Ad9u0WoaFhtuA58xN-oMFLID26qRBgJCQ7XVeIV4xHrHFaOa2bcxRlmmcXYUXHZUVVyVLYfZpiOH1vuFsMb5-b6GKOoRLSgaFbJQbkbDA2_nqi-HYyxDXhDyN8knGIzey3KS4EqFRG4yyphbnB_uYe4ddJplVvbfzloh8wzzPxd4fAuqYwexnYP5NEo2Xcm8AlLkgV-
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1bT9swFICPRvcAPLBx79aBkZB4CrR2HCeP1TZULi1SFSTeIsd2JAS0qLQIeNpP2G_cL5mPc-nKhJDgMYqdOLaPzyXHnwF2GYtS4UvppdwIz7c6yIuagUtc45E2qFYwNNDtBZ1z__iCl9mEuBcm50NUATeUDLdeo4BjQPpgSg2V2oGDrEYLrc6fg494rLfzqvpTghQa6A63x7gXBX5Ychub9GC2_qxe-s_YnLVdnfI5_ARp2ew85-RqfzJO99XTM6Lju77rMywVpilp53NpGT6YwQos_gMsXIWzNik41aTzeDt8uJR_fv3uF2m294Z0y8N2CVKvJG4sJNYqJvHkZjiyRWOXd240iXOYwRqcH_6Mv3e84kgGTzGBXUh5GCg_UyJIQ6atryZUmgkuhEGWoDRUZipjVEfWzQozzYVkVNlVgra0b3zJ1qE2GA7MJhDeNEozFfhIwJFhJBEh3JIp18L6OEzVwSsHJFEFrxyPzbhOctIyTbCjkqqj6rBXlb_NSR0vlmyU45sUEnuXoF2JdEHeqsNOddvKGv5AkQMznGAZuyBaF07YR2zk86J6lTVMeWRXzDpQN7qvtCFp_-i2q6svb6m0DfOduHuanB71Tr7CAsVAgMsjbkBtPJqYb9ZaGqdbTh7-AqUGCZk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1bT9swFICPuEgTe2CwwSjjYqRJewq0vsTJY0WpyqUwoSLxFjm2IyGgraBFG0_8BH7jfsl8nAuUaUKCxyh24tg-N-f4M8B3xuJUcqWCVFgZcGeDgrge-sQ1ERuLZgWXBrrHYeeMH5yL82e7-HM-RLXghpLh9TUK-NBkO0_QUGU8N8gZtMiZ_GmY5WE9wnndOn0CSKF_7ml7TARxyKMS21inO5P1J83SP77mpOvqbU_7E6iy1XnKyeX2eJRu6_sXQMf3fNYCzBeOKWnmM2kRpmz_M3x8hiv8AidNUlCqSef3cPDrQv15eDwtkmzvLOmWR-0SZF4p3FZInE9MeuPrwY0r2vNZ59aQXo4yWIKz9l5vtxMUBzIEmknsQSqiUPNMyzCNmHGRmtRpJoWUFkmCylKV6YxRE7sgK8qMkIpR7XQEbRhuuWLLMNMf9O0KEFG32jAdcuTfqChWCBBuqFQY6SIcpmsQlOOR6IJWjodmXCU5Z5km2FFJ1VE1-FGVH-acjv-WXCuHNynk9TZBrxLZgqJRg63qtpM0_H2i-nYwxjJOHboATrpHfM2nRfUq55aK2OnLGlA_uK-0IWm2us3qavUtlTbhw89WOznaPz78BnMUVwF8EvEazIxuxnbduUqjdMNLw1-VVQhR
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+General+Hypoxia-Responsive+Molecular+Container+for+Tumor-Targeted+Therapy&rft.jtitle=Advanced+materials+%28Weinheim%29&rft.au=Zhang%2C+Tian-Xing&rft.au=Zhang%2C+Zhan-Zhan&rft.au=Yue%2C+Yu-Xin&rft.au=Hu%2C+Xin-Yue&rft.date=2020-07-01&rft.eissn=1521-4095&rft.spage=e1908435&rft_id=info:doi/10.1002%2Fadma.201908435&rft_id=info%3Apmid%2F32459030&rft.externalDocID=32459030
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0935-9648&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0935-9648&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0935-9648&client=summon